SCHEMBL16922011

SCHEMBL16922011

CNCCN(C)c1noc(=O)[nH]1

nearest known ligand 0.51

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CTH P32929 1/20 0.51
PRMT3 O60678 1/20 0.33
CARM1 Q86X55 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
PRMT1 Q99873 1/20 0.33
PRMT8 Q9NR22 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16922056 0.90 CTH (0.49) CTH
SCHEMBL15598033 0.82 CTH (0.54) CTH
SCHEMBL16921704 0.81 CTH (0.56) CTH
SCHEMBL16921854 0.81 CTH (0.56) CTH
SCHEMBL16922036 0.80 PRMT3 (0.33) CTHPRMT3CARM1PRMT6PRMT1
SCHEMBL16921776 0.77 CTH (0.60) CTH
SCHEMBL16921844 0.77 CTH (0.51) CTH
SCHEMBL15597865 0.76 CTH (0.51) CTH
SCHEMBL16921931 0.72 CTH (0.55) CTH
SCHEMBL16921964 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170327478-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS, INC. 2017-11-16 US disclosed
US-9725426-B2 Cystathionine-γ-lyase (CSE) inhibitors SOVA PHARMACEUTICALS, INC. (US) 2017-08-08 US disclosed
US-20150272934-A1 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS SOVA PHARMACEUTICALS, INC. 2015-10-01 US disclosed
US-20150266837-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS, INC. 2015-09-24 US disclosed
US-20150202186-A1 CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN SOVA PHARMACEUTICALS, INC. 2015-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170327478-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS CBS, CTH, BHMT CTH 2/4885PRMT3 348/4885CARM1 771/4885
US-20150266837-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS CBS, CTH, BHMT CTH 2/4885PRMT3 348/4885CARM1 771/4885
US-20150202186-A1 CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN CBS, CTH, MTR CTH 2/4885PRMT3 1194/4885CARM1 2651/4885
US-20150272934-A1 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS HIF1AN, CBS, COXFA4L2 CTH 4/4885PRMT3 292/4885CARM1 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.